Belay Diagnostics
Belay Diagnostics reads tumour DNA from cerebrospinal fluid, giving brain and spinal cord tumours a liquid biopsy when a tissue biopsy is risky or impossible, and telling true progression from treatment effects on scans.
Overview
Belay Diagnostics, based in Chicago, offers cerebrospinal fluid liquid biopsy for primary and metastatic tumours of the central nervous system: genomic profiling to find targetable alterations when tissue is unavailable, and longitudinal monitoring to detect recurrence and to distinguish pseudoprogression from real progression. The tests are physician-ordered.
Similar pages
not linked directly; found by shared links- CompanyEpistamai Biotech
Shares Comprehensive genomic profiling and the tag fcct-directory.
- CompanyHartwig Medical Foundation
Shares Comprehensive genomic profiling and the tag fcct-directory.
- CompanyOncoDNA
Shares Comprehensive genomic profiling and the tag fcct-directory.
- CompanyProtean BioDiagnostics
Shares Comprehensive genomic profiling and the tag fcct-directory.
- CompanyCeGaT
Shares Comprehensive genomic profiling and the tag fcct-directory.
- InstitutionCeCurio (MVZ Tübingen oncology)
Shares Glioma & glioblastoma and the tag fcct-directory.
- CompanyCNSide Diagnostics
Shares Liquid biopsy (ctDNA) and the tag fcct-directory.
- CompanyRGCC International
Shares Liquid biopsy (ctDNA) and the tag fcct-directory.